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Wnt/β-catenin signaling is crucial for intestinal carcinogenesis and the maintenance of
intestinal cancer stem cells. Here we identify the histone methyltransferase Mll1 as a reg-
ulator of Wnt-driven intestinal cancer. Mll1 is highly expressed in Lgr5+ stem cells and
human colon carcinomas with increased nuclear β-catenin. High levels of MLL1 are associated
with poor survival of colon cancer patients. The genetic ablation of Mll1 in mice prevents
Wnt/β-catenin-driven adenoma formation from Lgr5+ intestinal stem cells. Ablation of Mll1
decreases the self-renewal of human colon cancer spheres and halts tumor growth of
xenografts. Mll1 controls the expression of stem cell genes including the Wnt/β-catenin
target gene Lgr5. Upon the loss of Mll1, histone methylation at the stem cell promoters
switches from activating H3K4 tri-methylation to repressive H3K27 tri-methylation, indi-
cating that Mll1 sustains stem cell gene expression by antagonizing gene silencing through
polycomb repressive complex 2 (PRC2)-mediated H3K27 tri-methylation. Transcriptome
profiling of Wnt-mutated intestinal tumor-initiating cells reveals that Mll1 regulates Gata4/6
transcription factors, known to sustain cancer stemness and to control goblet cell differ-
entiation. Our results demonstrate that Mll1 is an essential epigenetic regulator of Wnt/β-
catenin-induced intestinal tumorigenesis and cancer stemness.
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Wnt/β-catenin signaling controls the self-renewal ofadult stem cells and promotes oncogenesis1–4. Acti-vated Wnt/β-catenin signaling is associated with colon
cancer and many other human cancers5–7. The inactivation of the
destruction complex composed of APC, Gsk3β, and Axin1/2 sta-
bilizes β-catenin, which would otherwise be phosphorylated and
ubiquitinated for proteasomal degradation8,9. Stabilized β-catenin
translocates to the nucleus, where it binds to Tcf/Lef1 tran-
scription factors and induces the expression of target genes such
as Axin210,11. Mutations in Wnt signaling components initiate
intestinal tumorigenesis by promoting the aberrant stability and
hyperactivity of β-catenin12,13.
Adult intestinal stem cells have been identified as the cells-of-
origin of intestinal cancer14. Actively proliferating stem cells,
which were initially described as crypt base columnar (CBC) cells,
reside in stem cell niches located at the base of intestinal crypts.
These cells constantly produce progenitor cells that differentiate
into absorptive enterocytes and secretory cells, including Paneth,
goblet, enteroendocrine, and tuft cells15. Inverse gradients of Wnt
and Bmp signaling organize the intestinal epithelium in pro-
liferative crypt and differentiated villus compartments. The
intestinal stem cells express the leucine-rich repeat-containing G-
protein coupled receptor Lgr5, which was discovered in the colon
cancer cell line Ls174T16,17. High Wnt/β-catenin signaling in the
crypts induces Lgr5 expression and is crucial for stem cell
maintenance17–19. Aberrant Wnt signaling in the intestinal stem
cells expands the stem cell compartment and initiates
tumorigenesis14.
Oncogenic Wnt signaling activates a stem cell gene expression
program in colon cancer cells and confers cancer stemness20.
Current therapies for colon cancer are often ineffective because
cancer stem cells can resist conventional chemotherapy and
initiate tumor relapse and metastasis. Epigenetic therapies hold
great promise for inhibiting tumor growth and cancer stemness21.
Oncogenic Wnt signaling has been shown to drive salivary gland
and head and neck tumorigenesis by exploiting the epigenetic
regulator Mll122,23. Mll1 is a trithorax homolog histone methyl-
transferase of the Mixed lineage leukemia (Mll/Kmt2) family,
which tri-methylates histone 3 at lysine 4 (H3K4me3), a chro-
matin mark that is enriched at the transcription start sites (TSS)
of active genes. H3K4 tri-methylation antagonizes gene repres-
sion through H3K27 tri-methylation by polycomb complexes24.
A role for Mll1 in Wnt-driven colon cancer has not yet been
determined.
In this work, we identify the histone methyltransferase Mll1 as
an epigenetic regulator of human and mouse intestinal cancer
stem cells and tumors. Mll1 promotes β-catenin-induced intest-
inal stem cell expansion and tumorigenesis, and controls the self-
renewal of colon cancer stem cells. Cancer stem cells are depleted
upon loss of Mll1, which sustains oncogenic Wnt-induced
stemness by antagonizing Polycomb Group (PcG)-mediated
silencing of key stem cell genes.
Results
Mll1 is upregulated in Wnt-high human colon cancer. We used
immunohistochemistry to assess the expression of the histone
methyltransferase MLL1 in human colon cancer biopsies. Colon
carcinomas showed substantial MLL1 expression at all tumor
stages (T0–T4), scored from weak to moderate and strong (Fig. 1a
and Supplementary Fig. 1a). The majority of tumors exhibited
moderate to strong MLL1 expression, which was not associated to
any particular tumor stage. We used a large transcriptomic colon
cancer patient data set (n= 1095) to evaluate the association of
MLL1 with disease progression. These analyses showed no sig-
nificant changes in MLL1 expression across tumor stages
(Supplementary Fig. 1b). Patients of stages I-III and stage IV were
stratified in three groups based on the level of MLL1 expression
(MLL1 low, medium, and high, Supplementary Fig. 1c). High
MLL1 levels were associated with shorter survival and increased
risk of disease relapse (Supplementary Fig. 1c, d). Immuno-
staining for β-catenin revealed high levels of nuclear β-catenin,
indicative of high Wnt signaling, in a major portion of the ana-
lyzed tumors (Supplementary Fig. 1e). Across all tumor stages,
carcinomas with high levels of nuclear β-catenin showed strong
expression of MLL1 (Fig. 1b and Supplementary Fig. 1f, g). The
data reveal that high MLL1 levels in colon cancer are associated
with poor patient survival and correlate to high Wnt activity.
Mll1 is highly expressed in Wnt-activated crypts and Lgr5+
intestinal stem cells. Lgr5+ intestinal stem cells have been
identified as the cells-of-origin in colon cancer14. High Wnt
activity (Wnthigh) in the intestinal crypts sustains Lgr5+ stem
cells that constantly produce secretory and absorptive progeni-
tors. These progenitors migrate out of the Wnthigh niche and
differentiate when they reach the villus compartment enriched for
differentiation-inducing factors such as Bmp415,25 (see schemes
in Fig. 1c). We used immunofluorescence to examine the
expression of the histone methyltransferase Mll1 along the
crypt–villus axis of mice. Mll1 expression is high at the base of the
crypt and in Ki67+ proliferating cells of the transit-amplifying
(TA) zone. Mll1 is gradually lost towards the differentiated
compartment (Fig. 1d and Supplementary Fig. 1h). We observed
the highest expression of Mll1 in the stem cells which were
identified by the Lgr5-EGFP-IRES-CreERT2 reporter16 (Fig. 1e,
white arrows). Paneth cells were distinguished from adjacent stem
cells by immunofluorescence for Mmp726 (Fig. 1e, white aster-
isks). Quantitative immunofluorescence confirmed the strongest
expression of Mll1 in Lgr5+ stem cells; it gradually decreased in
the TA cells, Paneth cells, and enterocytes (Fig. 1f). A crypt–villus
gradient was also observed for H3K4 tri-methylation (H3K4me3)
(Supplementary Fig. 1i). We observed a similar distribution of
Mll1, Ki67, and H3K4me3 in the mouse colon (Supplementary
Fig. 1j–l).
The high expression of Mll1 in the Wnthigh crypt compartment
and particularly in Lgr5+ stem cells suggested that Mll1 is crucial
for stemness and is lost upon differentiation. The composition of
growth factors that are essential for intestinal organoid cultures
mimics the intestinal crypt stem cell niches27. Modulating stem
cell niche properties in small intestinal organoids through the
removal of Noggin and administration of Bmp4 led to a reduction
of the expression of Mll1, accompanied by a repression of the
stem cell gene Lgr5 in a concentration-dependent manner
(Fig. 1g). The activation of Bmp signaling and the triggering of
differentiation was confirmed by our observation of an increase in
the expression of the Bmp target gene Id228. Stimulating Wnt
activity by adding the Wnt ligand Wnt3a increased the expression
of Mll1 (Fig. 1g). Wnt3a treatment also increased the expression
of the Wnt-regulated stem cell gene Lgr5 and the classical Wnt
target Axin211 (Fig. 1g). Inverse Wnt/Bmp gradients define the
crypt stem cell niches and the differentiated villus compartments
of the intestinal epithelium15,25. Our data thus reveal that the
opposing Wnt/Bmp gradients restrict Mll1 expression to the
Wnt-activated crypt cells.
Mll1 is required for the β-cateninGOF-induced intestinal
tumorigenesis. We addressed the role of Mll1 in Wnt-driven
intestinal tumorigenesis using a tamoxifen-inducible genetic
mouse model16,29. Lgr5-EGFP-IRES-CreERT2; β-catenindeltaEx3/+
mice produce a stabilized oncogenic form of β-catenin (β-catGOF,
deleted for the N-terminal phosphorylation and ubiquitination
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Fig. 1 High Mll1 expression in colon carcinomas and Lgr5+ intestinal stem cells. a Immunohistochemistry for MLL1 (upper panel) and β-catenin (lower
panel) of colon cancer patient biopsies, tumor stage T0, scale bar 50 µm. Insets on the right, scale bar 20 µm. Stainings were performed on eight
independent biopsies. b Quantification of nuclear β-catenin staining in tumors with strong, moderate, and weak expression of MLL1, scored as low and high
across all tumor stages, n= 39 biologically independent colon cancer specimen. Chi-square test for significance, χ2= 11.5, p= 0.0032. c Scheme of the
murine small intestine crypt–villus axis63. In the lower crypt, Lgr5+ stem cells (green) intersperse between Paneth cells (yellow). Stem cells produce
progeny that proliferate and differentiate in the transit-amplifying (TA) zone. Terminally differentiated cells, e.g. enterocytes and goblet cells, move into the
villus. Opposing gradients of Wnt and Bmp signaling specify proliferation and differentiation along the crypt–villus axis. d Representative
immunofluorescence staining for Mll1 (red) on the small intestine of Lgr5-GFP mice reveals a gradual decrease in Mll1 expression from the crypt to villus.
Stem cells marked by Lgr5-GFP (green), nuclei in blue (DAPI), scale bar 20 µm. Stainings were performed in five independent mice. e Magnification of the
crypt region; upper panel, arrows mark stem cells with high Mll1 expression (red); bottom panel, asterisks mark Paneth cells stained by Mmp7 (yellow)
with low Mll1 expression. E-cadherin (white) stains cell borders. Nuclei in blue (DAPI), scale bar 10 µm. f Quantification of Mll1 staining intensity in nuclei
of crypt and villus cells, normalized to the mean Mll1 expression in TA cells located just above the stem cell niche (up to relative+ 8 position), quantified
from independent stainings of five mice. Data are presented as mean values ± 95% confidence interval, outliers are shown as single dots. Mann–Whitney
test (two-tailed) for significance relative to stem cells, ***p= 0.0009, ****p < 0.0001. g Mll1, Lgr5, Id2, and Axin2 mRNA expression in intestinal organoids
of mice treated with 10 ng/ml and 100 ng/ml Bmp4 and 0.66 µg/ml recombinant Wnt3a for 24 h, n= 6 independent experiments for control and Wnt3a,
n= 3 for 10 ng/ml Bmp4, n= 5 for 100 ng/ml Bmp4, two-tailed unpaired t-test, Mll1 *p= 0.0329, ***p= 0.0001; Lgr5 ****p < 0.0001, ***p= 0.0004; Id2
****p < 0.0001, ***p= 0.0008; Axin2 *p= 0.0136, ****p < 0.0001, ***p= 0.0005. Data are presented as mean values ± SD. Source data are provided as a
Source Data file.
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sites) in Lgr5+ stem cells, which is known to induce tumor-
igenesis. We then crossed the Lgr5-EGFP-IRES-CreERT2; β-
catGOF mice with Mll1flox mice30 to ablate Mll1 specifically in the
Lgr5+ stem cells. The activation of β-catenin and loss of Mll1 in
stem cells was induced in Lgr5-EGFP-IRES-CreERT2; β-catGOF;
Mll1flox/+ and Lgr5-EGFP-IRES-CreERT2; β-catGOF; Mll1flox/flox
mice by intraperitoneal injection of tamoxifen (hereafter called β-
catGOF; Mll1+/− and β-catGOF; Mll1−/− mice). Mice were ana-
lyzed at several time points up to 100 days post-induction. The
intestines of the β-catGOF; Mll1+/− mice became severely dys-
plastic within 30 days and developed adenomas which were
highly proliferative, as indicated by Ki67 staining, and contained
islets with high Mll1 expression (Fig. 2a, upper panel). In con-
trast, the homozygous deletion of Mll1 led to the normal
crypt–villus structures in β-catGOF; Mll1−/− mice, with pro-
liferation restricted to the crypt regions (Fig. 2a, lower panel). We
observed Mll1-depleted crypts among non-recombined Mll1-
expressing crypts (Fig. 2a, inset in the lower right image). Thus,
the homozygous deletion of Mll1 prevented β-cateninGOF-
induced intestinal tumorigenesis, as also shown by a
Kaplan–Meier plot of tumor incidence (Fig. 2b).
Mll1 sustains the β-cateninGOF-driven tumorigenic Lgr5+ stem
cell expansion. The dysplastic tissue in the β-catGOF; Mll1+/−
intestines showed an expansion of Lgr5-GFP+ stem cells (Fig. 2c,
upper picture, Supplementary Fig. 2a) and an increase in the stem
cell genes Lgr5, Smoc2, and Cd44 (Supplementary Fig. 2b). The
stem cell expansion in β-catGOF tumorous intestines was asso-
ciated with an increase in Mll1 protein levels (Supplementary
Fig. 2c, the mutant β-catenin allele is marked by an arrow,
quantification is shown below). Specifically, tumor cells with high
levels of β-catenin expressed high nuclear levels of Mll1 (Sup-
plementary Fig. 2d; green arrows mark β-cateninhigh cells, white
arrowheads indicate β-cateninlow cells). Remarkably, the homo-
zygous loss of Mll1 prevented the Wnt/β-catenin-mediated
expansion of stem cells (Fig. 2c, lower picture). A LacZ reporter
allele31 allowed us to trace recombined cells and their progeny.
Equal recombination was observed at day 5 in 25% of crypts
(Supplementary Fig. 2e, upper row, quantification in f). Subse-
quently, the mutant cells in β-catGOF; Mll1+/− mice expanded at
day 10 and formed LacZ+ dysplasia at day 30 (Supplementary
Fig. 2e, middle and lower left pictures, quantification in f). In
contrast, β-catGOF; Mll1−/− mice showed a gradual reduction of
LacZ+ cells down to 10% over time (Supplementary Fig. 2e, lower
right picture, quantification in f). At 30 days, the β-catGOF;
Mll1−/− mice exhibited crypts with LacZ+ long-lived Paneth cells
interspersed with non-mutant (LacZ−) stem cells (Supplementary
Fig. 2g, marked by an arrow). Furthermore, we observed crypts
that were normally shaped and depleted of Mll1 but with nuclear
β-catenin (β-catGOF) and positive for Lgr5-GFP; they exhibited a
slight reduction in proliferation, as seen by a decrease in the
incorporation of BrdU (Fig. 2c, lower picture, Supplementary
Fig. 2h, i). Apoptosis was not detected in β-catGOF; Mll1−/−
crypts (Supplementary Fig. 2j).
Intestinal organoids established from Lgr5-EGFP-IRES-
CreERT2 mice recapitulated the pattern of Mll1 expression
observed in control (wildtype) intestines: highest expression is
seen in Wnt-dependent Lgr5-GFP+ stem cells (Fig. 2d, e, left
panel). Organoids from β-catGOF, β-catGOF; Mll1+/− and β-
catGOF; Mll1−/− mice were mutated in culture by in vitro
recombination with 4-hydroxy-tamoxifen. All β-catGOF orga-
noids grew independently of R-spondin1 (Supplementary Fig. 2k).
β-catGOF induced a strong expansion of Lgr5-GFP+ stem cells
(Fig. 2d, e, second panel). This expansion was maintained in
organoids with heterozygous deletion of Mll1, β-catGOF; Mll1+/−
(Fig. 2d, e, third panel). In contrast, homozygous deletion of Mll1,
β-catGOF; Mll1−/−, prevented the expansion of the stem cell
population (Fig. 2d, e, fourth panel). Western blotting for Lgr5-
GFP confirmed the stem cell expansion phenotype (Fig. 2f,
quantification below). β-catGOF; Mll1−/− organoids exhibited a
decrease in the expression of the intestinal stem cell genes Lgr5,
Smoc2, and Olfm4 (Fig. 2g). The expression of the Wnt-regulated
stem cell gene Ascl232 and the classical Wnt target gene Axin211
were unaffected by deletion of Mll1 (Fig. 2g). Single β-catGOF;
Mll1−/− cells re-formed spheroid-shaped organoids over many
passages with high efficiency (Supplementary Fig. 2l), demon-
strating the proliferative potential and self-renewal capacity of
Mll1-deficient β-catGOF cells. From the seventh passage on, β-
catGOF; Mll1−/− cells formed less organoids, which were smaller
and acquired a thick-walled shape (Supplementary Fig. 2m),
indicating differentiation and progressive exhaustion of stemness
upon loss of Mll1.
Under non-oncogenic conditions without genetic stabilization
of β-catenin, mutant Mll1−/− stem cells produced progeny up to
20 days after the induction of mutagenesis, as seen by LacZ lineage
tracing in Mll1−/− mice (Supplementary Fig. 3a, quantification
on the right). From 20 days onwards, Mll1−/− crypts were
progressively lost, but a substantial number of Mll1−/− crypts
persisted beyond 50 days after induction (Supplementary Fig. 3b,
quantification on the right). The Mll1−/− mice did not show any
obvious abnormalities, the intestinal epithelium remained intact,
and the overall organ function was not visibly impeded. In
summary, these data demonstrate by genetic means that Mll1 is
essential for the β-catGOF-dependent stem cell expansion
and tumorigenesis. The loss of Mll1 did not interfere with
β-catGOF function per se, but β-catGOF; Mll1−/− stem cells
progressively lost their self-renewal capacity. This indicates that
Mll1 is crucial to maintain the stemness of β-catenin-activated
intestinal stem cells.
Ablation of Mll1 induces differentiation of β-catenin-activated
stem cells. We isolated the Lgr5-GFP+ intestinal stem cells from
β-catGOF; Mll1+/− and β-catGOF; Mll1−/− mice using FACS and
analyzed transcriptomic changes by RNA sequencing. This
revealed that β-catGOF; Mll1+/− stem cells became Paneth cell-
like, which was caused by high Wnt activity due to the β-catGOF
mutation33. Immunofluorescence of β-catGOF; Mll1+/− tumor
sections and RT-PCR analysis of β-catGOF-mutants revealed a
strong expression of the Paneth cell marker Mmp726 (Fig. 3a). A
volcano plot of the differentially expressed genes in β catGOF;
Mll1−/− versus β-catGOF; Mll1+/− stem cells showed both up- and
downregulation of genes (Fig. 3b and Supplementary Data 1). This
included a global increase in the expression of goblet cell-specific
genes, among these Tff3 (Itf) and Muc234. Downregulated genes
included specific markers of Paneth cells, e.g., Defa5, Defa17,
Lyz126, indicating that ablation of Mll1 shifted the Paneth-like
identity of β-catGOF stem cells towards a goblet cell fate. Genes
specific for enteroendocrine and tuft cells did not undergo major
changes (Supplementary Fig. 3c). β-catGOF; Mll1−/− stem cells
exhibited a strongly increased expression of Atoh1, a transcription
factor essential for secretory lineage determination35, and its target
gene Spdef, which instructs secretory cell differentiation in Paneth
and goblet cells36,37 (Fig. 3b). The expression of Hes1, a Notch-
controlled transcription factor that represses Atoh1 expression38,
was not downregulated in the β-catGOF; Mll1−/− stem cells. There
were also no decreases in other Notch target genes such as
Hes5 and Hey1 (Supplementary Data 1), which means that
the upregulation of Atoh1 occurs independently of a global
decrease in Notch signaling. The Paneth cell gene Mmp7 was
increased in β-catGOF; Mll1−/− stem cells, indicating priming
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Fig. 2 The β-cateninGOF-induced intestinal stem cell expansion and tumorigenesis depend on Mll1. a Sections of intestines of Lgr5-EGFP-IRES-CreERT2;
β-catGOF; Mll1+/− and Lgr5-EGFP-IRES-CreERT2; β-catGOF; Mll1−/− mice, called β-catGOF; Mll1+/− and β-catGOF; Mll1−/−, at 30 days after induction with
tamoxifen: H&E staining (left), scale bar 50 µm; Ki67 staining (middle), nuclei counterstained with hematoxylin, scale bar 100 µm; Mll1
immunohistochemistry (right), scale bar 50 µm, with the magnification of Mll1 knockout crypt in inset, scale bar 20 µm. Stainings were performed on
sections of three independent mice per genotype. b Kaplan–Meier plot of tumor incidence in β-catGOF; Mll1+/− and β-catGOF; Mll1−/− mice.
c Immunofluorescence for Lgr5-GFP stem cells (green) and β-catenin (red) on intestinal sections of β-catGOF; Mll1+/− and β-catGOF; Mll1−/− mice at day
30 after induction, scale bar 100 µm. Insets a, b immunostaining for Lgr5-GFP (green) and Mll1 (red) on serial sections, scale bar 20 µm. Stainings were
performed on sections of three independent mice. d Fluorescence live imaging of non-induced (control) and tamoxifen-induced Lgr5-GFP-IRES-CreERT2; β-
catGOF, Lgr5-GFP-IRES-CreERT2; β-catGOF; Mll1+/− and Lgr5-GFP-IRES-CreERT2; β-catGOF; Mll1−/− mouse intestinal organoids. Lgr5-GFP (green) marks
intestinal stem cells, scale bars 100 µm. Representative images from three independent experiments with three biologically independent organoid lines.
e Immunofluorescence staining for Lgr5-GFP (green) and Mll1 (red) on sections of organoids of the four genotypes, nuclei in blue (DAPI), scale bars 30
µm. Representative stainings from three independent experiments. f Western blot for Lgr5-GFP in control and tamoxifen-induced β-catGOF, β-catGOF;
Mll1+/−, and β-catGOF; Mll1−/− organoids of mice, vinculin as a control for equal loading. Quantification of Lgr5-GFP protein levels in mutant organoids
relative to controls below, n= 2 samples from two independent experiments processed in parallel for western blotting. g mRNA expression of Mll1 and
intestinal stem cell genes in β-catGOF; Mll1+/− and β-catGOF; Mll1−/− mouse organoids relative to β-catGOF organoids, n= 4 independent experiments,
two-tailed unpaired t-test, Mll1 **p= 0.005, Smoc2 *p= 0.032, Olfm4 **p= 0.037. Data are presented as mean values ± SD. Source data are provided as a
Source Data file.
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Fig. 3 The ablation of Mll1 induces differentiation. a Left: Immunostaining for Mmp7 (green) and Mll1 (red) on β-catGOF; Mll1+/− tumor sections, scale
bars 50 µm. Nuclei stained with DAPI (blue), E-cadherin (yellow) stains cell borders. Right: mRNA expression of Mmp7 in control and β-catGOF intestines,
n= 3 independent mice, two-tailed unpaired t-test, **p= 0.0012. Data are presented as mean values ± SD. b Volcano plot of differentially expressed genes
in β-catGOF; Mll1−/− relative to β-catGOF; Mll1+/− Lgr5-GFP+ stem cells isolated from four independent mice each, represented as blue dots. Cut-off log2
fold-change ≥ 0.5. Goblet and Paneth cell-specific genes78 are marked in red and green, respectively, and indicated by names. c Immunostaining on
sections of adjacent non-recombined (left) and recombined (right) small intestinal crypts in β-catGOF; Mll1−/− mice, left: for Mmp7 (green) and Mll1 (red),
middle: for Mll1 (brown) and Alcian blue; nuclear counterstaining with hematoxylin. Right: immunostaining for Lyz (green) and ITF (red), scale bar 20 µm.
Insets on the right: magnifications of mutant double-positive cells, scale bars 10 µm. Nuclei stained with DAPI (blue), E-cadherin (yellow) stains cell
borders. Stainings were performed in two independent mice per genotype. d Volcano plot of differentially expressed stem cell genes and transcription
factors in β-catGOF; Mll1−/− relative to β-catGOF; Mll1+/− Lgr5-GFP+ stem cells isolated from four independent mice each, represented as dark blue dots.
Cut-off log2 fold-change ≥ 0.5. e Immunostaining for Gata4 (yellow, upper panel) and Mll1 (red, lower panel) on sections of adjacent non-recombined
(left) and recombined (right) small intestinal crypts in β-catGOF; Mll1−/− mice, scale bars 20 µm. Nuclei stained with DAPI (blue). Stainings were
performed on sections of six independent mice. f mRNA expression of Gata4, Bmp4 (n= 4 independent experiments) and the secretory differentiation
markers Mmp7 and Muc2 (n= 7 independent experiments) in β-catGOF; Mll1+/− and β-catGOF; Mll1−/− organoids, two-tailed unpaired t-test, Gata4 **p=
0.0032, Bmp4 ****p < 0.0001, Mmp7 ***p= 0.001, Muc2 **p= 0.0096. Data are presented as mean values ± SD. Source data are provided as a Source
Data file.
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towards a mixed Paneth-goblet state. Mll1-deficient crypts of β-
catGOF; Mll1−/− mutant mice exhibited large cells that were
double-positive for Paneth cell (Mmp7 and Lyz) and goblet cell
markers (Alcian blue (mucin) and ITF) (right crypt in Fig. 3c).
Such Paneth-goblet intermediate cells were not observed in adja-
cent non-recombined Mll1-expressing crypts on the same section
(left crypt in Fig. 3c).
RNA sequencing of the sorted Lgr5-GFP+ stem cells also
revealed that β-catGOF; Mll1−/− stem cells exhibited a decreased
expression of several transcription factors and stem cell genes. As
illustrated in a volcano plot, Mll1-deficient β-catGOF stem cells
showed a decreased expression of the intestinal stem cell gene
Olfm4. Lgr5 and Smoc2 expression was not significantly altered
(Fig. 3d). The ablation of Mll1 did not affect the expression of the
classical Wnt target gene Axin2 (Fig. 3d), as was observed in β-
catGOF; Mll1−/− organoids. In β-catGOF; Mll1−/− stem cells, the
expression of the transcription factors Foxa1 and Gata4 was
downregulated (Fig. 3d), the latter of which had previously been
proposed as an Mll1 target gene39. Immunostaining confirmed a
strong reduction of the GATA binding protein 4 (Gata4) in Mll1-
deficient crypts, compared to non-recombined Mll1-expressing
crypts on sections of β-catGOF; Mll1−/− small intestines (Fig. 3e).
Gata4/6 transcription factors had previously been reported to
repress Bmp4, thereby maintaining colon cancer stemness40. RT-
PCR analysis of β-catGOF; Mll1−/− organoids confirmed a
decreased expression of Gata4 and revealed a concomitant
upregulation of Bmp4 and the secretory differentiation markers
Mmp7 and Muc2 (Fig. 3f), identifying Mll1 as an upstream
regulator of Gata4/Bmp4-controlled cancer stemness and differ-
entiation. In conclusion, the stem cell transcriptome showed that
ablation of Mll1 primed β-catGOF intestinal stem cells for
differentiation and shifted the Wnt-imposed Paneth-like identity
towards a goblet cell fate. Thus, Mll1 maintains stemness by
restricting the differentiation of β-catGOF intestinal stem cells.
Mll1 sustains the stemness and tumorigenicity of human colon
cancer cells. To investigate the essential role of Mll1 in the
stemness of human colon tumors, we established stable,
doxycycline-inducible shMLL1 single-cell clones of the human
colon adenocarcinoma cell lines Ls174T and DLD1, which
exhibited a strong reduction of MLL1 (Supplementary Fig. 4a–d).
In all experiments, shMLL1 cells were compared with non-
induced and non-targeted shRNA (control) cells. The ablation of
MLL1 did not affect the expression of other MLL family members
(Supplementary Fig. 4e). Serial re-plating assays revealed that the
ablation of MLL1 did not immediately affect the viability and
proliferation of Ls174T and DLD1 cells in adherent 2D cultures.
A significant growth reduction was detected only after four pas-
sages and a total of 10–14 days of culture (Supplementary Fig. 4f,
g). We found that MLL1 protein was strongly increased in 3D
(non-adherent, self-renewing) sphere cultures of human
Ls174T cells compared to adherent cultures, while the expression
of the family member SETD1A was not changed (Supplementary
Fig. 4h, quantification on the right). In contrast to the 2D culture,
the ablation of MLL1 in 3D sphere cultures had a rapid effect on
the growth and self-renewal of the tumor cells: secondary sphere
formation of shMLL1 cells was reduced by 80% in Ls174T and by
60% in DLD1 cells, compared to control cells (Fig. 4a and Sup-
plementary Fig. 4i, quantifications on the right). Residual
shMLL1 spheres exhibited minimal MLL1 expression and
reduced proliferation, as shown by staining for Ki67 (Supple-
mentary Fig. 4j). shMLL1 spheres were negative for the apoptosis
marker cleaved Caspase-3 (Supplementary Fig. 4k, western blot
on the right).
To test the in vivo growth and tumor-forming capacities of the
shMLL1 cells, doxycycline-induced shMLL1 and control Ls174T
colon cancer cells were subcutaneously engrafted in nude mice.
Mice inoculated with shMLL1 cells were administered doxycy-
cline throughout the experiment. Control cells formed large
tumors within 28 days (Fig. 4b). In contrast, tumor formation by
shMLL1 cells was reduced by 75%. The residual xenografts
showed a strong reduction of MLL1 (Supplementary Fig. 4l,
quantification below) and H3K4me3 (Supplementary Fig. 4m,
upper panel), and significantly fewer proliferating cells (Supple-
mentary Fig. 4m, middle panel, quantifications on the right). The
apoptosis marker cleaved Caspase-3 did not increase in shMLL1
Ls174T tumors (Supplementary Fig. 4m, lower panel, western
blot on the right). The shMLL1 human Ls174T xenografts and
sphere cells showed enhanced differentiation with an increase in
the expression of the Paneth cell-specific genes DEFA5 and LYZ
and the goblet cell markers MUC2 and ITF (Supplementary
Fig. 4n), as was also observed in the β-catGOF mouse tumor
model. An increase in ITF expression was also observed in
DLD1 sphere cells (Supplementary Fig. 4o). The expression of the
differentiation-associated cell cycle inhibitor p21 was upregulated
in shMLL1 Ls174T xenografts and spheres (Supplementary
Fig. 4p, q, quantifications on the right). These data show that
MLL1 is crucial for stemness and tumor formation of human
colon cancer cells.
Mll1 regulates specific stem cell genes to sustain colon cancer
stemness. We used RNA sequencing to investigate transcriptomic
changes upon knockdown of MLL1 in the human colon cancer
cells. Comparison of the differentially expressed genes with a
signature of Mll1-ablated fibroblasts39 revealed deregulation of
MLL1 target genes such as SMOC2 and ENPP1 (Supplementary
Fig. 4r, Supplementary Data 2). The human shMLL1 colon cancer
cells showed a decrease of the expression of FOXA1 and the
GATA4 colon homolog GATA6, which we had identified as Mll1-
regulated genes in murine β-catGOF; Mll1−/− stem cells. Com-
parisons with intestinal stem cell signatures reported by the
groups of Clevers41, Soshnikova42, and Batlle20 revealed a sig-
nificant gene overlap (Fig. 4c: Clevers 36, Soshnikova 106, and
Batlle 19 genes). We compiled 132 deregulated stem cell genes to
establish an MLL1-regulated colon cancer stem cell signature
(Supplementary Data 3). A volcano plot of the deregulated genes
overlaid with this signature showed a predominant down-
regulation of stem cell genes upon knockdown of MLL1; these
included OLFM4, SMOC2, IGFBP4, and the Wnt-regulated gene
LGR541 (Supplementary Data 3 and Fig. 4d). RT-PCR analyses of
sphere cultures confirmed the decrease in the expression of the
stem cell genes LGR5, IGFBP4, SMOC2, and OLFM4. The
expression of CD44 and LRIG141 was not significantly decreased.
There was no reduction in the expression of the Wnt-regulated
genes ASCL2, SOX943, and AXIN2 (Fig. 4e). The selective reg-
ulation of Wnt-dependent stem cell genes was also observed in
DLD1 human colon cancer cells (Supplementary Fig. 4s). The
ablation of MLL1 did not affect the overall activity of Wnt signaling,
as shown by a Tcf/Lef luciferase reporter assay (TOPflash)44 in
comparison to cells either treated with the Wnt activator
CHIR9902145 or the Wnt inhibitor LF346 (Fig. 4f).
Mll1 regulates the H3K4me3–H3K27me3 balance at specific
stem cell genes. Chromatin immunoprecipitation (ChIP)
revealed high H3K4me3 and low H3K27me3 levels at the tran-
scription start sites (TSS) of the MLL1-regulated stem cell genes
LGR5, SMOC2, OLFM4, and IGFBP4 (Fig. 5a and Supplementary
Fig. 5a). Ablation of MLL1 shifted the epigenetic state of the stem
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cell genes from transcriptionally permissive (H3K4me3) to
repressed (H3K27me3) (Fig. 5a and Supplementary Fig. 5a).
There were no changes in levels of H3K4me3 or H3K27me3 at
the TSS of ASCL2 and AXIN2 (Fig. 5a, right). Global levels of
H3K4 and H3K27 methylation were not changed (Supplementary
Fig. 5b). We identified MLL1 binding to the promoters of the
intestinal stem cell genes LGR5, SMOC2, IGFBP4, and OLFM4
(Fig. 5b and Supplementary Fig. 5c, d). ChIP specificity was
confirmed by MLL1 binding to MECOM, an MLL1 target gene47,
and by comparison to a negative control region (TAL1+ 7048).
Fig. 4 Mll1 sustains colon cancer stemness. a Brightfield images and MLL1 immunofluorescence (green) of control and 6d doxycycline-induced shMLL1
human Ls174T spheres, scale bar 100 µm, magnification of brightfield images 25 µm, immunofluorescence 20 µm. Quantification of spheres >50 µm in size
on the right, n= 3 biologically independent samples, two-tailed unpaired t-test, **p= 0.0013. Data are presented as mean values ± SD. b Xenografts of
control and shMLL1 Ls174T cells in NMRInu/nu mice. Mice inoculated with shMLL1 cells were administered doxycycline from day −1 throughout the
experiment. Left: tumor growth curves plotted as median with range, n= 6 independent animals inoculated with three biologically independent induced or
non-induced shMLL1 Ls174T cell clones in duplicates over two independent experiments, two-tailed unpaired t-test, d16 **p= 0.007, d21 ***p= 0.0034,
d23 ***p= 0.00016, d28 ***p= 0.00018. Right: dissected tumors at day 28, scale bar 2 cm. c Differentially expressed genes in shMLL1 human
Ls174T cells, cut-offs log2 fold-change ≥ 0.5, adjusted p-value ≤ 0.05, compared to intestinal stem cell signatures reported by the groups of Clevers,
Soshnikova, and Batlle. The correlation table indicates the number of common genes, the Jaccard index of similarity is encoded in green color shadings
(lighter means more similar). d Volcano plot of differentially expressed genes in shMLL1 human Ls174T cells (blue dots), overlaid with MLL1-regulated
colon cancer stem cell signature (Supplementary Data 3), marked as green dots and indicated by name. e mRNA expression of intestinal stem cell genes
and classical Wnt targets in control and 6d doxycycline-induced shMLL1 human Ls174T spheres, n= 4 samples derived from three biologically independent
cell clones (IGFBP4, OLFM4 n= 3), two-tailed unpaired t-test, LGR5 ***p= 0.001, IGFBP4 **p= 0.0018, SMOC2 *p= 0.015, OLFM4 *p= 0.03. Data are
presented as mean values ± SD. f Tcf/Lef luciferase reporter assays in control and shMLL1 cells treated with doxycycline for 10 days, n= 6 samples over
three independent experiments, two-tailed unpaired t-test. Wnt-responsive luciferase activity (TOPflash) calculated relative to control (FOPflash). 3 µM
CHIR99021 and 50 µM LF3 were added for 24 h to stimulate and repress Wnt signaling, respectively, n= 3 independent experiments, two-tailed unpaired
t-test, ***p= 0.0002, **p= 0.0074. Data are presented as mean values ± SD. Source data are provided as a Source Data file.
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Strongly reduced binding of MLL1 was observed in shMLL1
Ls174T and DLD1 cells (Fig. 5b and Supplementary Fig. 5c–e). At
the LGR5 promoter, ChIP revealed no change in β-catenin/TCF4
occupancy upon MLL1 ablation (Fig. 5c, d). In the absence of
MLL1, LGR5 expression is thus repressed by promoter-associated
H3K27me3, despite occupancy of the promoter by β-catenin/
TCF4. Our data indicate that MLL1 controls stem cell gene
activity by modulating active and repressive promoter histone
methylation marks.
Antagonistic control of Lgr5 by Mll1 and PcG. H3K27me3
marks are deposited by the polycomb repressive complex 2
(PRC2)24. Inhibition of the catalytic PRC2 subunit EZH2 with
Gsk12649 partially restored the decreased expression of the
MLL1-regulated stem cell genes LGR5 and OLFM4, even in the
absence of MLL1 (Fig. 6a). H3K4me3 marks at the TSS of LGR5
and OLFM4 were not restored upon Gsk126 treatment
(Fig. 6b), indicating that the re-initiation of LGR5 and OLFM4
expression was independent of MLL1 and its methyltransferase
activity. The expression of the MLL1-independent Wnt target
genes ASCL2 and AXIN2 was unaffected by Gsk126 treatment
(Fig. 6c), and H3K4me3 and H3K27me3 TSS marks were
unchanged (Fig. 6d). Taken together, our data show that the
histone methyltransferase MLL1 sustains the oncogenic Wnt-
driven expression of specific stem cell genes by antagonizing
PcG-mediated gene silencing. In the absence of MLL1, PRC2
catalyzes the tri-methylation of H3K27me3 and mediates gene
repression. In the case of LGR5, this occurs regardless of the
promoter occupancy of β-catenin/TCF4 (summarized in the
schemes in Fig. 6e). Overall, our data show that Wnt-dependent
stem cell genes are differentially controlled by epigenetic reg-
ulators, and reveal MLL1 as crucial for the maintenance of
human colon cancer stemness.
Discussion
Here we demonstrate a crucial role for the epigenetic regulator
Mll1 in Wnt/β-catenin-driven intestinal tumor formation and
cancer stemness. We show that Mll1 promotes the β-cateninGOF-
induced expansion of Lgr5+ intestinal stem cells. Mll1 is highly
expressed in Lgr5+ stem cells and human colon cancer specimens
with high levels of nuclear β-catenin. The expression of Mll1
increased upon enhanced Wnt/β-catenin activity, indicating that
canonical Wnt signaling controls Mll1 expression. Recently, we
have shown that the Mll1 promoter harbors functional Tcf4
binding sites, and that Mll1 expression is increased in Wnt-driven
salivary gland and head and neck tumor models23. We now
demonstrate that Mll1 mediates a differential response of Wnt-
dependent stem cell genes in colon cancer. Mll1 does not interfere
with the global activity of Wnt signaling, but controls its outcome
at the level of gene regulation.
Fig. 5 Mll1 directly regulates intestinal stem cell genes. a ChIP for H3K4me3 and H3K27me3 at TSSs of LGR5, SMOC2 (n= 7 samples derived from two
biologically independent cell clones over four independent experiments), ASCL2 and AXIN2 (n= 4 samples derived from two biologically independent cell
clones over two independent experiments) in non-induced control (light gray columns), and 11d doxycycline-induced shMLL1 Ls174T cells (black columns),
represented as % input. Two-tailed unpaired t-test, significance calculated for control versus shMLL1, LGR5 TSS ***p= 0.0002, ****p < 0.0001; SMOC2 TSS
****p < 0.0001, **p= 0.0082. b ChIP for MLL1 in non-induced control (light gray columns) and 6d doxycycline-induced shMLL1 human Ls174T cells (black
columns) at the LGR5 promoter, negative control region+ 70 kb downstream of the TAL1 promoter, represented as % input, n= 6 control and n=
5 shMLL1 samples derived from two biologically independent cell clones over four independent experiments. Two-tailed unpaired t-test, significance
calculated for control versus shMLL1 and IgG, *p= 0.0129, **p= 0.0042. ChIP for TCF4 (c) and β-catenin (d) at the LGR5 promoter in non-induced control
(light gray columns) and 6d doxycycline-induced shMLL1 human Ls174T cells (black columns), negative control region TAL1+ 70, represented as % input,
n= 5 (TCF4) and n= 6 samples (β-catenin) derived from two biologically independent cell clones over three independent experiments. Two-tailed
unpaired t-test, significance calculated for control versus shMLL1 and IgG, TCF4 *p= 0.03, β-catenin *p= 0.02. All data are presented as mean values ±
SD. Source data are provided as a Source Data file.
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The expression of a stabilized oncogenic form of β-catenin in
Lgr5+ stem cells produced intestinal tumors with a high
expression of intestinal stem cell genes. Stem-like gene expression
profiles are indicative of high tumor-initiating potential and self-
renewal capacity of colon cancer cells20. In particular, tumors
with increased levels of Lgr5 have malignant potential and are
invasive and aggressive50. Genetic ablation of Lgr5+ stem cells by
diptheria toxin halts colon cancer growth, revealing the relevance
of these stem cells for tumorigenesis51. The genetic loss of Mll1
prevented β-cateninGOF-driven intestinal tumorigenesis. Ablation
of Mll1 halted tumor growth in a xenograft model and reduced
the Wnt-imposed stem cell gene expression profile in colon
cancer cells. We found that Mll1 controls selective stem cell
genes. It regulated the expression of the stem cell marker Lgr516,
whereas it did not regulate the expression of the Wnt targets
Axin211, Sox943, or Ascl232. Lgr5 expression critically depends on
Mll1: in the absence of Mll1, β-catenin binding was not sufficient
to activate Lgr5 expression. Mll1 also controls the intestinal stem
cell genes Smoc2, Igfbp4, and Olfm4, which are induced in Wnt-
mutated cancer cells but regulated by other signaling pathways
such as Notch and NF-κB52,53.
Mechanistically, Mll1 sustained the expression of stem cell
genes in Wnt-activated tumor cells by antagonizing PcG-
mediated silencing. Mll1 knockdown resulted in a switch of
activating H3K4me3 to repressive H3K27me3 chromatin marks
at the transcription start sites of Lgr5, Smoc2, Igfbp4, and Olfm4.
Strikingly, the inhibition of the polycomb H3K27 tri-
methyltransferase Ezh2 with Gsk12654 partially restored the
expression of Lgr5 in Mll1-deficient cells despite the absence of
Mll1 and H3K4me3 marks. This implies that Mll1 and its
H3K4me3 activity are dispensable for initiating Lgr5 expression
but crucial for preventing PRC2-mediated silencing of the Lgr5
promoter55. These observations concord with the opposition
between trithorax and Polycomb group proteins in Drosophila56.
Remarkably, the genetic inactivation of the polycomb complex
PRC1 in oncogenic Wnt-activated intestinal stem cells also has a
tumor-preventive effect57, implying that PRC1 plays a role in
promoting Wnt-driven intestinal tumorigenesis. Further, PRC2
ablation in the mouse intestine causes loss of stem cells and
aberrant secretory differentiation by deregulating Wnt signaling
and cell proliferation58. Apparently, a fine-tuned balance of active
and repressive histone modifications is essential for the
Fig. 6 Mll1 antagonizes PcG-mediated silencing of stem cell genes. a mRNA expression of LGR5 and OLFM4 in control (dark gray), 6d doxycycline-
induced shMLL1 human Ls174T cells (dark green), and shMLL1 Ls174T cells following 4-day Gsk126 treatment (light green), n= 4 independent
experiments, two-tailed unpaired t-test, LGR5 *p= 0.014, **p= 0.0016, *p= 0.027; OLFM4 **p= 0.008, *p= 0.03. Data are presented as mean values ±
SD. b ChIP for H3K4me3 (dark gray columns) and H3K27me3 (light gray columns) at the TSSs of LGR5 and OLFM4 (n= 3 independent experiments) in
control, 11d doxycycline-induced shMLL1 human Ls174T cells, and shMLL1 Ls174T cells following 4-day Gsk126 treatment, represented as % input. Data are
presented as mean values ± SD. c mRNA expression of ASCL2 and AXIN2 in control (dark gray), 6d doxycycline-induced shMLL1 human Ls174T cells (dark
green), and shMLL1 Ls174T cells following 4-day Gsk126 treatment (light green), n= 6 independent experiments, two-tailed unpaired t-test. Data are
presented as mean values ± SD. d ChIP for H3K4me3 (dark gray columns) and H3K27me3 (light gray columns) at the TSSs of ASCL2 and AXIN2 (n= 3
independent experiments) in control, 11d doxycycline-induced shMLL1 human Ls174T cells, and shMLL1 Ls174T cells following 4-day Gsk126 treatment,
represented as % input. Data are presented as mean values ± SD. e Scheme of β-catenin/TCF4/MLL1-dependent regulation of LGR5 in colon cancer cells.
MLL1 prevents PRC2-mediated gene silencing to sustain LGR5 expression. This is associated with the MLL1-dependent H3K4 tri-methylation at the LGR5
TSS. Ablation of MLL1 results in PRC2-mediated H3K27me3 and silencing of LGR5 expression. Source data are provided as a Source Data file.
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maintenance of intestinal stem and tumor-initiating cells, a reg-
ulatory mechanism of stemness in which Mll1 is crucially
involved.
Lineage tracing experiments revealed that the number of Mll1-
deficient cells diminished over time. This was not due to apop-
tosis caused by the ablation of Mll1. Individual Mll1-deficient
intestinal stem cells in β-catGOF; Mll1−/− mice persisted up to
100 days after induction and were capable of producing progeny.
These mutant cells did not expand into tumors, although they
exhibited nuclear β-catenin. Our studies in organoids revealed
that the ablation of Mll1 did not immediately eliminate β-catGOF
stem cells but progressively exhausted their stemness. Through
transcriptome profiling of FACS-isolated Lgr5+ intestinal stem
cells at 10 days after mutagenesis, we determined that the ablation
of Mll1 in β-catGOF stem cells instructed a goblet cell differ-
entiation program. Residual Mll1 knockout crypts in β-catGOF;
Mll1−/− mice revealed cells positive for goblet and Paneth cell
markers, demonstrating a secretory differentiation of β-catGOF
stem cells upon ablation of Mll1. Mll1-deficient stem cells and
crypts showed a strong decrease in levels of the transcription
factors Foxa1 and Gata4. High levels of Foxa1 expression were
observed in poorly differentiated colon cancer, and Gata6, the
colon homolog of Gata4, participates in the regulation of stem-
ness by preventing Bmp4-induced differentiation in Wnt-driven
colon cancer40,59. Moreover, β-catGOF; Mll1−/− stem cells
exhibited an increase in the expression of Atoh1, a transcription
factor that instructs secretory lineage differentiation35. The
ablation of Gata4 has previously been shown to increase intestinal
Atoh1 levels60. Gata4-deficient intestines exhibit enhanced levels
of Atoh1 and increased numbers of goblet cells60,61. Our data
support a Gata4-mediated restriction of Atoh1 expression and
goblet cell differentiation. We further identify Mll1 as an
upstream regulator of a Gata4–Atoh1 axis that controls stemness
versus secretory goblet cell differentiation.
Altogether, our data show that the epigenetic regulator Mll1
promotes the initiation and growth of Wnt-driven colon cancer
by maintaining stemness and preventing the differentiation of
Wnt-activated tumor-initiating and cancer stem cells. By sus-
taining Gata4/6 expression and directly controlling specific stem
cell genes, Mll1 promotes stemness and prevents secretory goblet
cell differentiation of Wnt-activated cancer cells.
Methods
Mice. Mice were bred in pathogen-free conditions, and care and use of animals
were performed according to the European and national regulations, published in
the Official Journal of the European Union L 276/33, September 22, 2010. All
animal procedures were approved by the Landesamt für Gesundheit und Soziales
(LaGeSo) Berlin with the number G101/18. Mice were housed in IVC cages type II
at 21 °C ambient temperature, 50–60% humidity, and a 12-h dark/light cycle.
Transgenic mouse lines used have been previously described: Lgr5-EGFP-IRES-
CreERT216, β-catGOF29, Gt(ROSA)26Sortm1Sor31, Mll1flox30. Mutagenesis was
induced in 4–6-weeks-old mice by intraperitoneal injections of tamoxifen (Sigma,
50 mg/kg, diluted 1:10 in sunflower oil) on three consecutive days. Mice were
analyzed at the indicated time points after the last tamoxifen injection. Mice were
given i.p. injections of BrdU (Millipore), final concentration 50 µg/g of body weight
in PBS at 2 h before sacrifice. Kaplan–Meier plot for tumor incidence was calcu-
lated based on macroscopic observation of hyperplastic intestinal tissue. Both
females and males were analyzed.
Isolation of Lgr5-GFP+ intestinal stem cells and RNA sequencing. For isolation
of Lgr5+ stem cells, crypts were dissociated into single cells with TrypLE Express
(ThermoFisher Scientific) for 30 min at 37 °C. Dissociated cells were passed
through a 70 µm cell strainer and washed wit 5% FBS/PBS. Cells were stained with
APC-conjugated anti-326 (EpCAM) antibody (1:100 dilution, eBioscience, Cat no.
17-5791-80), Alexa-Fluor 700 CD45 antibody (1:50 dilution, BD, Cat no. 560693)
and PE-conjugated anti-CD24 (1:100 dilution, eBioscience, Cat. no. 12-0242-81)
for 45 min on ice. Stained cells were collected by centrifugation and resuspended in
SYTOX blue dead cell stain (1:20,000 dilution, ThermoFisher Scientific). FACS
sorting was performed on a FACS AriaTM III cell sorter (BD). 300 single cells were
sorted into a PCR tube containing 2 µl of nuclease-free H2O with 0.2% Triton-X
100 and 4 U murine RNase Inhibitor (NEB), and stored at −80 °C. RNA isolation
and library preparation were performed based on the Smart-seq2 protocol62. In
brief, RNA was denatured for 3 min at 72 °C in the presence of 2.4 mM dNTP
(Invitrogen), 240 nM dT-primer, and 4U RNase Inhibitor (NEB), and reverse
transcribed using the Superscript II Reverse Transcriptase (Invitrogen). Single-
stranded cDNA was amplified with the Kapa HiFi HotStart Readymix (Roche) and
purified using Sera-Mag SpeedBeads (GE Healthcare). cDNA quality and con-
centration were determined with the Fragment Analyzer (Agilent). Sequencing was
performed on a NextSeq 500 (Illumina) with a sample sequencing depth of 30mio
reads on average. RNA seq reads were aligned to the mm10 transcriptome with
GSNAP (version 2018-07-04). Read counts for each gene were extracted using
featureCounts (version 1.6.3). A table of read counts per gene was generated based
on the overlap of uniquely mapped reads with the Ensemble Gene annotation
(version 92). Read counts were subjected to statistical analysis using the DESeq2 R
package (version 1.22.2). Euclidean distance analysis of the normalized counts was
performed to compute the sample-to-sample correlation. Read counts from dif-
ferent biological groups were subjected to differential expression analysis with
DESeq2, a maximum of 10% false discoveries (10% FDR) was accepted. Volcano
plots were generated by a generic R X–Y plotting using the log2FoldChange versus
the log2 adjusted p-values. RNA seq differential expression data can be found in
Supplementary Data 1.
Organoid culture. Intestinal organoids were obtained as previously described63:
small intestines of mice were dissected and dissociated in 8 mM EDTA/PBS for 5
min at RT followed by 20 min incubation in ice-cold 2 mM EDTA/PBS at 4 °C. The
epithelia were fractionated by shaking in ice-cold PBS. 250 crypts were seeded in
20 µl of growth factor-reduced Matrigel (BD Matrigel #356231) and cultured in
basic crypt medium (60/40 Advanced DMEM/F12 supplemented with N2 and B27,
GlutaMax, N-Acetylcysteine and Penicillin/Streptomycin (Invitrogen)) containing
50 ng/ml mEGF (Gibco), 100 ng/ml mNoggin (Peprotech) and 500 ng/ml hR-
Spondin1 (Peprotech). Organoids were split every 4–6 days by mechanical dis-
ruption. Cre-mediated recombination was induced by the addition of 800 nM 4-
hydroxy-tamoxifen for 2 days. β-catGOF organoids were selected by R-Spondin1
withdrawal. All analyses were performed at 7–10 days after mutagenesis. Recom-
binant human BMP4 (Peprotech) was added for 24 h in Noggin-free crypt medium
supplemented with EGF and R-spondin1. For serial re-plating, β-catGOF; Mll1−/−
organoids were dissociated into single cells with TrypLE Express (ThermoFisher
Scientific) for 5 min at 37 °C, and 2000 cells were seeded in 20 µl of growth factor-
reduced Matrigel and cultured in crypt medium supplemented with mEGF,
mNoggin, and hR-spondin1.
Cell culture. HEK293TN cells and DLD1 and Ls174T human colon cancer cell
lines were cultured in 1xDMEM supplemented with 10% fetal bovine serum (FBS)
and 1%Penicillin/Streptomycin (PenStrep) at 37 °C and 5% CO2. Cell line identity
was confirmed by Multiplex human Cell line Authentication (MCA, Multiplexion).
For non-adherent sphere cultures, dishes were coated with 12 mg/ml polyhema/
95% EtOH (Sigma) overnight at 55 °C. Single cells were cultured in CSC medium
(DMEM/F12 (1:1)+GlutaMAX (Gibco), 1%PenStrep, supplemented with N2, 10
ng/ml bFGF (Gibco) and 10 ng/ml hEGF (Peprotech)) for 4–5 days, then dis-
sociated with Trypsin for 5 min at 37 °C, and re-plated in CSC medium on
polyhema-coated dishes. After 1 day of secondary sphere culture, spheres were
harvested by centrifugation and processed for RNA/protein analyses. For serial re-
plating assays, cells were seeded at a density of 0.5 × 106 cells on 10cm-dishes,
trypsinized and counted every 2-3 days, and re-plated at a density of 0.5 × 106 cells.
Gsk126 was administered for 96 h at 5 µM (McCabe et al. 2012)54. Tcf/Lef luci-
ferase reporter assay (TOPflash) was performed as previously described44, 3 µM
CHIR99021 (Axon #1386) and 50 µM LF346 were added for 24 h.
Generation of lentiviral particles and lentiviral transduction. Doxycycline-
inducible shRNA knockdown cell lines were generated by lentiviral transduction,
using the doxycycline-inducible pInducer11 system64. shRNA targeting MLL1 was
designed with the optimized miR30a backbone65 (sequence shMLL1: TGCTGTT
GACAGTGAGCGAAAGAAAGATTCTAAAAGTATATAGTGAAGCCACAGAT
GTATATACTTTTAGAATCTTTCTTCTGCCTACTGCCTCGGA). For the pro-
duction of lentiviral particles, HEK293TN cells were co-transfected with 10 µg
pPAX.2, 2.5 µg pMD2.G and 10 µg pInducer11-shMLL1 by transfection with PEI
(Sigma). Supernatants containing lentiviral particles were collected at 24 and 48 h
after transfection. For lentiviral transduction, the lentiviral particle-containing
supernatant was mixed 1:1 with a fresh growth medium containing 8 µg/ml
polybrene. Ls174T and DLD1 cells were transduced at 300 g for 1 h at RT followed
by incubating overnight at 37 °C. Transduced cells with high expression of shRNA
were selected by fluorescence-activated cell sorting (FACS) for GFP and tRFP64
and cultured as single-cell clones to establish shMLL1 cell lines. Knockdown was
induced by the addition of doxycycline to the growth medium at a final con-
centration of 300 ng/ml.
Xenografts. 1 × 106 cells in 200 µl PBS were injected under the skin of nude mice,
NMRI:nu/nu, female. In the case of shMLL1 cells, the inducible shMLL1 lines were
pre-treated with 300 ng/ml doxycycline for 4 days, and mice were administered
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-020-20222-z ARTICLE
NATURE COMMUNICATIONS |         (2020) 11:6422 | https://doi.org/10.1038/s41467-020-20222-z | www.nature.com/naturecommunications 11
doxycycline in drinking water (2 mg/ml doxycycline in 5 g/l sucrose) from day −1
throughout the experiment. Tumor size and mouse body weight were measured
every other day.
Histology, immunofluorescence staining, and analysis. Analysis of human naïve
colon cancer biopsies was approved by the ethic commission of the Friedrich-
Alexander Universität Erlangen-Nürnberg (148_19 BC). Informed consent was
obtained from all patients. Murine tissue was fixed in 4% formaldehyde/PBS, and
histological analyses were performed on 5–7 µm paraffin sections. Organoids were
fixed in 4% formaldehyde/PBS for 1 h and embedded in 1.5% agarose/PBS. For
LacZ whole-mount staining, murine intestine was cut open longitudinally, fixed for
2 h in ice-cold fixative (1% formaldehyde, 0.2% glutaraldehyde, 0.02% NP-40 in
PBS), washed twice in PBS and incubated in staining solution (2 mM MgCl2, 5 mM
K3Fe(CN)6, 5 mM K4Fe(CN)6, 0.01% NP-40, 0.01% sodium deoxycholate, 1 mg/ml
X-gal (Roth) in PBS) overnight at RT protected from light. 10 µm paraffin sections
of LacZ-stained tissue were counter-stained with nuclear fast red. For Mll1
immunostaining, antigen retrieval was performed by boiling in 10 mM sodium
citrate pH 6.0 for 15 min, and sections were permeabilized in ice-cold methanol for
10 min prior to incubation in blocking solution (0.1% Tween20, 10% horse serum,
1% BSA in PBS) followed by incubation of the primary antibody overnight at 4 °C.
Fluorochrome-conjugated or HRP-coupled secondary antibodies were incubated
for 1 h at RT. Immunohistochemistry was developed with the DAB chromogenic
substrate (DAKO).
Light microscopy and data analysis. Representative z-stacks were acquired with
inverted laser scanning microscopes LSM710 and LSM700 using 405, 488, 561, and
633 nm lasers and a PlanApochromat ×40 NA 1.3 objective (Zeiss Jena, Germany)
or a spinning disc confocal microscope CSU-W1 (Nikon/Andor) equipped with an
iXON888 camera, using PlanApo ×20 NA 0.75 and Apo LWD ×40 NA 1.15
objectives. Images were processed using the software Zeiss ZEN (blue edition).
Brightfield images were acquired with a Leica DIM6000 microscope equipped with
a NPlan ×10 NA 0.25 and a motorized LMT200 V3 High precision Scanning Stage,
using the Leica Application Suite X (LAS X). Images were analyzed with Fiji
ImageJ. Mean fluorescence intensity in 3D reconstructed samples was quantified
with Imaris 8 (Bitplane/Andor) software, using the surface module and selecting
for nuclear fluorescence signal with a mask created in the DAPI channel.
Mll1 staining intensity in the crypt cell populations was quantified with the
measurement point tool in Imaris 8 and normalized to the staining intensity in the
TA cell population.
Chromatin immunoprecipitation. Chromatin immunoprecipitation (ChIP) of
histone modifications was performed from pInd11-shMLL1 Ls174T cell lines
induced with 300 ng/ml doxycycline for 11d, following the instructions of the
iDEAL ChIP-seq kit for histones (Diagenode). For ChIP of Mll1, TCF4, and β-
catenin, pInd11-shMLL1 Ls174T and DLD1 cell lines were induced with 300 ng/ml
doxycycline for 6d, and chromatin was prepared using the ChIP-IT Express kit
(Active Motif). Cells were grown to 80% confluency, trypsinized for 3 min at 37 °C,
fixed in 1% formaldehyde for 10 min, and quenched in glycine for 5 min at RT.
Chromatin was sheared with a Branson Sonifier 450 (3 min shearing time, duty
cycle 60, output control 6, sonified 10× for histone ChIPs, 4× for Mll1 ChIPs, 1 min
pause between each sonication round). Shearing efficiency was checked on a 1%
agarose gel. 10 µg of sheared chromatin was used for Mll1 ChIPs. ChIP-qPCR
analysis was performed in a total volume of 20 µl SYBR green reaction mix (Roche
Diagnostics) containing 0.25 µM of forward and reverse primers each in a CFX96-
C1000T thermal cycler (BioRad): 2 min at 50 °C and 2min at 95 °C followed by 42
cycles of 15 s at 95 °C and 1 min at 60 °C. Ct values of precipitated DNA were
calculated relative to input DNA (% input). ChIP-qPCR primers were designed
using H3K4 methylation profiles available in the UCSC genome browser (human
reference genome GRCh37/hg19) and the Mll1 ChIP-seq UCSC genome browser
data set from Active Motif (https://www.activemotif.com/catalog/details/61295/
mll-hrx-antibody-pab). Primer sequences used for ChIP-qPCR are given in Sup-
plementary Information (Supplementary Table 1).
Western blotting. Organoids were harvested and washed once in ice-cold 0.1%
BSA-PBS, and cells were washed twice in PBS prior to lysis in ice-cold RIPA buffer
(50 mM Tris pH8.0, 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deox-
ycholate) containing protease inhibitors (cOmplete Mini EDTA-free, Roche). Total
cell extracts were separated on polyacrylamide gels and transferred to a nitro-
cellulose membrane via semidry transfer for 1 h 15 min at 90 mA or wet transfer
for 3 h at 85 V and 4 °C. Membranes were blocked with 5% BSA or 5% skim milk in
0.1% Tween20/TBS and probed with primary antibody diluted in blocking solution
overnight at 4 °C. HRP-conjugated secondary antibodies were incubated for 1 h at
RT. Immunoblots were developed with Western Lightning Plus ECL (Perkin
Elmer) for 3 min and imaged with a Vilber Lourmat imaging system FUSION SL-3.
Uncropped scans of Western blots are provided in the Source Data file.
Antibodies. The following antibodies were used in this study (dilutions given for
immunostaining/Western Blot): anti-Mll1 (D6G8N, Cell Signaling #14197, 1:100/
1:2000, 1:50 for ChIP), anti-hSet1 (Bethyl A300-289A, 1:2000), anti-H3K4me3
(Cell Signaling #9727, 1:2000/1:10,000, 1:50 for ChIP), anti-H3K27me3 (Millipore
07-449, 1:1000, 5 µg for ChIP), anti-H3K4me2 (Millipore #07-436, 1:5000), anti-
H3K4me1 (Millipore #07-030, 1:5000), anti-H3 (Abcam ab1791, 1:10,000), anti-
p21 (Santa Cruz sc-6246, 1:100/1:1000), anti-cleaved Caspase-3 (Cell Signaling
#9661, 1:400/1:2000), anti-E-cadherin (BD 610181, 1:200), anti-Mmp7 (Santa Cruz,
1:100), anti-GATA4 (Santa Cruz Biotechnology sc-25310, RRID:AB_627667,
1:200), anti-GFP (Abcam ab6673, 1:500), anti-Ki67 (ThermoFisher MA5-14520,
1:300), anti-BrdU (Abcam ab6326, 1:100), anti-β-catenin (BD 610153, 1:300/
1:1000, 3 µg for ChIP), anti-TCF4 (Cell Signaling #2569, 1:50 for ChIP), anti-Lyz
(DAKO A0099, 1:500), anti-ITF (Santa Cruz sc-18272, 1:300), anti-alpha Tubulin
(Sigma, 1:10,000), and anti-Vinculin antibody (Sigma V9131, 1:5000). For
immunofluorescence and immunohistochemistry, cyanine-labeled secondary
antibodies (Jackson ImmunoResearch) and HRP-conjugated polymer and DAB
reagent (DAKO) were used. ChIP control antibodies were rabbit monoclonal IgG
isotype control (Cell Signaling #3900) and mouse monoclonal IgG isotype control
(Santa Cruz sc-2025). The specificity of histone modification antibodies was con-
firmed by dot blotting against synthetic peptides carrying the modifications of
interest (Diagenode).
RNA preparation for qRT-PCR analysis and RNA sequencing. Total RNA was
isolated by Trizol extraction (Invitrogen) or with the NucleoSpin RNA isolation kit
(Macherey–Nagel). DNA contaminations were removed by DNase1 digestion
(Invitrogen) in the presence of RNase inhibitor (RNase Out, Invitrogen), and RNA
was purified via phenol/chloroform extraction. For qRT-PCR, 5 µg of total RNA
were reverse transcribed with random hexamer primers (Invitrogen) and MMLV
reverse transcriptase (Promega, 200 U/µl). qRT-PCR was performed in a total
volume of 20 µl SYBR green reaction mix (Roche Diagnostics) containing 0.25 µM
of forward and reverse primers each in a CFX96-C1000T thermal cycler (BioRad):
2 min at 50 °C and 2min at 95 °C followed by 42 cycles of 15 s at 95 °C and 1min
at 60 °C. All reactions were performed as duplicates. Expression of target genes in
treated versus control samples relative to the endogenous reference GAPDH was
calculated using the ΔΔCt method. Primer sequences used for qRT-PCR are listed
in Supplementary Information (Supplementary Table 2).
For RNA sequencing, total RNA from shMLL1 Ls174T cells induced with 300
ng/ml doxycycline for 3 days and from non-induced parental cells was isolated
with the NucleoSpin RNA isolation kit (Macherey–Nagel) and sequenced on a
NextSeq 500 (Illumina). RNA seq reads were quality-checked by FASTQC (v0.11.5)
software. Sequencing reads were mapped to the human whole genome (hg38) using
STAR aligner (v. 2.5.3a) and default parameters. Read counts for each gene
(gencode v12) were extracted from the BAM file using featureCounts software
(1.5.1). Read counts from different biological groups were subjected to differential
expression analysis using the DESeq2 R statistical package. Comparisons between
shMLL1 and parental control cells were corrected by individual technical replicates
(paired comparison). In order to avoid background signal/noise, genes with <10
reads over all samples were excluded before adjusting the p-value for multiple
testing. Genes with an adjusted p-value lower than 0.05 and absolute fold-change
(log10) higher than 0.5 were considered differentially expressed. Gene expression
profile comparison was performed by GeneOverlap R package by overlapping lists
of differentially expressed genes (MGI symbol) from different sources (Clevers41;
Soshnikova42; Batlle20) with our own data. All conversions from Ensembl ID to
MGI symbol and from human gene names to mouse gene names were performed
by biomaRt. Volcano plots were generated by a generic R X–Y plotting using the
log2FoldChange versus the log2 adjusted p-values. RNA seq differential expression
data can be found in Supplementary Data 2.
Human CRC transcriptomic data sets. Transcriptome analyses in human CRC
were carried out on 2207 samples that were available in two public repositories
(Supplementary Table 3): (i) RNA seq (version 2) data from The Cancer Genome
Atlas (TCGA) project (http://cancergenome.nih.gov/) were downloaded from the
legacy version of the NCI Genomic Data Commons (GDC) repository66. Clinical
and follow-up information was retrieved from the TCGA Pan-Cancer Clinical Data
Resource (CDR) for outcome analytics67. A total of 543 TCGA CRC samples were
available for analysis from this repository. (ii) Eight publicly available Affymetrix
microarray data sets were downloaded from the NCBI GEO repository68. These
data sets included gene expression and clinical information from a total of 1690
patients with CRC. In addition, clinical information for these data sets was
downloaded from the Synapse repository69 as provided by Guinney et al.70
(syn2623706), and used to complete missing data in the retrieved, when possible.
Processing of TCGA RNA seq data: Four different TCGA data sets were
processed separately, as colon and rectum samples had been sequenced
independently using two different platforms (Genome Analyzer and HiSeq). For
each of them, RSEM gene expression estimates were log2-transformed and quantile
normalized. Only primary tumors from patients with no previous cancer diagnosis
were kept for analyses. Patients with samples measured in the two platforms were
excluded from the GA version. Samples TCGA-A6-2679-01A and TCGA-AA-
A004-01A were also excluded, as their gene expression showed an anomalous
distribution as compared to the rest of the samples in their data set, even after
quantile normalization. A total of 543 TCGA CRC samples was available for
analysis.
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Processing of tumor microarray samples: Microarray samples were processed
separately for each data set using packages affy71 and affyPLM72 from
Bioconductor73. Raw CEL files were normalized using RMA background correction
and summarization74. Standard quality controls were performed in order to
identify abnormal samples and relevant sources of technical variability75 regarding
(a) spatial artifacts in the hybridization process (scan images and pseudo-images
from probe-level models); (b) intensity dependences of differences between chips
(MvA plots); (c) RNA quality (RNA digest plot); (d) global intensity levels (boxplot
of perfect match log-intensity distributions before and after normalization and RLE
plots); (e) anomalous intensity profile compared to the rest of samples (NUSE
plots, Principal Component Analysis). Technical information concerning sample
processing and hybridization was retrieved from the original CEL files: date of
scanning were collected in order to define scan batches in each data set separately,
and previously described technical metrics76 were computed and recorded as
additional features for each sample. Probesets were annotated using the
information available on the Affymetrix-Thermofisher web page (https://www.
thermofisher.com/es/es/home.html). No samples were excluded due to quality
issues, leaving a total of 1690 microarray samples available for analysis.
Calibration and integration of tumor transcriptomic data: To make their
expression values comparable, microarray data sets were corrected by potential
sources of technical biases. For doing so, a linear model was fitted to each probeset
and data set separately, in order to correct expression values by the center of origin
of the sample, batch (scanning day), and probeset differences captured by PM.IQR,
RMA.IQR and RNA.DEG metrics76. This correction was carried out using a
mixed-effect model in which microsatellite instability (MSI) status was also
included as a covariate. Scanning day was modeled as a random effect in these
models. Expression intensities were summarized at the gene level (entrez) by the
first principal component of the probesets mapping to the same gene. This
component was centered and scaled to the weighted mean of the probesets’ means
and standard deviations, where the contributions to this first component were used
as weights. The sign of this score was then corrected so that it was congruent to the
sign of the probeset contributing the most to the first component. TCGA RNA seq
expression data were processed in an analogous way; potential biases captured by
sample’s center and batch (plate) of origin were corrected using a mixed-effects
model for each gene and data set separately. In such models, the center was
modeled as a fixed effect while the plate identifier was included as a random effect.
The R package lme was used in this procedure. Data sets were merged after
quantile normalization and gene-wise standardization (median and median
absolute deviation) to the GSE39582 data set according to their distribution of
gender, age, site, MSI, and stage, when available. Such standardization was carried
out by inverse probability weighting using logistic regression (LogReg) model. For
doing so and for each data set D, a LogReg model was carried out on D and
GSE39582 that included the aforementioned clinical parameters as predictors of
the data set affiliation. Clinical parameters were included in the model as they were
informative according to the Akaike Information Criterion (AIC) after running a
forward step-wise algorithm for variables selection. Next, conditional probabilities
of belonging to data sets D and GSE39582 (Pd and Pr, respectively) were retrieved
from the model; then, weights were computed as the ratio of Pd/Pr; finally, weights
were truncated to value “five”, in order to avoid the overrepresentation of any
sample in the standardization process. Expression values were truncated to the
maximum and minimum values observed in this reference data set. Samples with
unknown tumor stage information were excluded from the data. As a result, this
CRC meta-cohort included a total of 2207 primary tumor samples for analyses.
Association of gene expression with clinical data in human CRC samples:
Association with gene expression levels was assessed using Cox proportional
hazards models (relapse and overall survival) and a linear model (stage). Statistical
significance was assessed by means of a Log-likelihood Ratio Test (Cox models) or
F-test (linear model), while Wald tests were used for pairwise comparisons. Sample
groups of low, medium, and high expression levels were defined using the tertiles of
the corresponding intensity distribution. Accordingly, hazard ratios (HR), adjusted
group means, and their corresponding 95% confidence intervals were computed as
measures of association. For visualization purposes, Kaplan–Meier survival curves
were estimated for groups of samples showing low, medium, and high gene
expression, while boxplots and stripcharts were built to display expression levels by
tumor stage.
Only samples from patients diagnosed at stage I, II, or III were considered for
analyses of time to relapse, for a total of 1095 samples. Overall survival analyses in
pre-metastatic (stages I–II–III) and metastatic (stage IV) tumors were carried out
on 981 and 165 samples, respectively. TCGA’s rectum samples were excluded from
these analyses accordingly to recommendations of the TCGA-Clinical Data
Resource (CDR)67. The threshold for statistical significance was set at 5%. All
analyses were carried out using R77.
Quantification and statistical analysis. All data are presented as mean ± SD unless
otherwise indicated. Statistical details of the experiments can be found in the figure
legends. Graphs and statistics were generated with GraphPad Prism software. Tests
for normal distribution were performed with D’Agostino–Pearson, and Shapiro–Wilk
tests. Significance (p-values) was determined with the Mann–Whitney test (two-
tailed) or two-tailed Student’s t-test. No statistical method was applied to estimate
sample size. No randomization or blinding protocol was used. Unless otherwise
indicated, n reports the number of independent biological replicates per experiment.
p-values ≤ 0.05 were considered statistically significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The RNA sequencing data from FACS-isolated Lgr5-GFP+ intestinal stem cells (Fig. 3b,
d and Supplementary Fig. 3c, Supplementary Data 1) have been deposited in the Gene
expression omnibus under accession number GSE148394. The RNA sequencing data
from shMLL1 Ls174T colon cancer cells (Fig. 4c, d and Supplementary Fig. 4r,
Supplementary Data 2) are available in the ArrayExpress database under accession
number E-MTAB-8152. The human colon cancer data referenced during the study
(Supplementary Table 3) are available in public repositories from the TCGA website
(TCGA-COAD, TCGA-READ) and in the Gene Expression Omnibus (GEO) at NCBI
(GSE14333, GSE33113, GSE39582, GSE38832, GSE44076, GSE13294, GSE18088 and
GSE2109). Clinical information was obtained from Synapse ID syn2623706. All the other
data supporting the findings of this study are available within the article and its
Supplementary Information files and from the corresponding authors upon reasonable
request. Source data are provided with this paper.
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